Zhengye Biotechnology Holding Limited (ZYBT)

Lumos Pharma Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	186.36	211.65	260.27	214.07
Revenue Growth (YoY)	-11.95%	-18.68%	21.58%	-
Cost of Revenue	95.06	94.14	112.39	89.45
Gross Profit	91.3	117.51	147.88	124.62
Selling, General & Admin	63.84	64.34	58.89	58.86
Research & Development	12.79	11.9	13.42	11.37
Operating Expenses	74.86	72.52	82.05	72.16
Operating Income	16.44	44.99	65.83	52.47
Interest Expense	-4.04	-4.42	-2.84	-1.05
Interest & Investment Income	0.23	0.31	0.11	0.11
Currency Exchange Gain (Loss)	0.68	-	-	-
Other Non Operating Income (Expenses)	1.09	2.89	0.81	1.62
EBT Excluding Unusual Items	14.39	43.76	63.91	53.15
Asset Writedown	-	-	-	-0.08
Pretax Income	14.39	43.76	63.91	53.07
Income Tax Expense	0.92	6.25	8.17	6.6
Earnings From Continuing Operations	13.47	37.51	55.74	46.47
Minority Interest in Earnings	-2.16	-6.05	-9.01	-7.51
Net Income	11.31	31.46	46.74	38.96
Net Income to Common	11.31	31.46	46.74	38.96
Net Income Growth	-64.04%	-32.69%	19.96%	-
Shares Outstanding (Basic)	46	46	46	46
Shares Outstanding (Diluted)	46	46	46	46
EPS (Basic)	0.25	0.69	1.02	0.85
EPS (Diluted)	0.25	0.69	1.02	0.85
EPS Growth	-64.04%	-32.69%	19.96%	-
Free Cash Flow	27.46	40.79	-9.99	12.75
Free Cash Flow Per Share	0.60	0.89	-0.22	0.28
Gross Margin	48.99%	55.52%	56.82%	58.22%
Operating Margin	8.82%	21.25%	25.30%	24.51%
Profit Margin	6.07%	14.86%	17.96%	18.20%
Free Cash Flow Margin	14.74%	19.27%	-3.84%	5.96%
EBITDA	40.6	68.9	84.63	68.48
EBITDA Margin	21.79%	32.55%	32.52%	31.99%
D&A For EBITDA	24.16	23.91	18.8	16.01
EBIT	16.44	44.99	65.83	52.47
EBIT Margin	8.82%	21.25%	25.29%	24.51%
Effective Tax Rate	6.42%	14.29%	12.79%	12.44%
Advertising Expenses	1.54	2.54	2.58	2.23

Updated Nov 15, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q